GSK

1,913

-0.26%↓

GSK

1,913

-0.26%↓

GSK

1,913

-0.26%↓

GSK

1,913

-0.26%↓

GSK

1,913

-0.26%↓

Home・Aandelen Lijst・AstraZeneca PLC
Search

AstraZeneca PLC

Gesloten

SectorGezondheidszorg

13,902 -1.08

Strong Buy

Prijsupdate 22 mei 2026, 15:29 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13880

Max

14116

Belangrijke statistieken

By Trading Economics

Inkomsten

1.6B

3.9B

Verkoop

-215M

15B

K/W

Sectorgemiddelde

27.887

49.701

EPS

1.29

Dividendrendement

1.74

Winstmarge

25.602

Werknemers

96,100

EBITDA

1.1B

5.7B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+14.79% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.74%

2.39%

Volgende Winsten

27 jul 2026

Volgende Ex Dividend datum

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3.5B

287B

Vorige openingsprijs

13903.08

Vorige sluitingsprijs

13902

Nieuwssentiment

By Acuity

34%

66%

81 / 345 Rangschikking in Healthcare

AstraZeneca PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 apr 2026, 16:28 UTC

Winsten

Correction to AstraZeneca Update

DJ

Lezen

29 apr 2026, 15:11 UTC

Winsten

AstraZeneca Plans U.K. Investment as Cancer Drugs Lift Revenue -- Update

DJ

Lezen

29 apr 2026, 06:31 UTC

Winsten

AstraZeneca Gets Revenue Boost From Cancer Drugs

DJ

Lezen

21 mei 2026, 11:06 UTC

Marktinformatie

AstraZeneca Set for Busy End of Year -- Market Talk

DJ

Lezen

13 mei 2026, 12:29 UTC

Marktinformatie

AstraZeneca Has Room to Grow in Heart Disease With Wainua -- Market Talk

DJ

Lezen

13 mei 2026, 11:54 UTC

Marktinformatie

AstraZeneca Has Credible Growth Path Beyond 2030 -- Market Talk

DJ

Lezen

1 mei 2026, 09:31 UTC

Marktinformatie

AstraZeneca Can Deal With Hit From FDA Cancer Drug Knockback -- Market Talk

DJ

Lezen

29 apr 2026, 10:29 UTC

Marktinformatie
Winsten

AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

DJ

Lezen

29 apr 2026, 10:06 UTC

Marktinformatie
Winsten

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

DJ

Lezen

29 apr 2026, 09:53 UTC

Marktinformatie
Winsten

AstraZeneca Seems in Fine Health -- Market Talk

DJ

Lezen

29 apr 2026, 06:05 UTC

Winsten

AstraZeneca Says It Remains on Track to Achieve Ambition for 2030, Beyond

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

AstraZeneca 1Q Ultomiris Revenue $1.27B, Up 18% at Constant Currency

DJ

Lezen

29 apr 2026, 06:04 UTC

Winsten

AstraZeneca 1Q Farxiga Revenue $2.19B, Down 2% at Constant Currency

DJ

Lezen

29 apr 2026, 06:03 UTC

Winsten

AstraZeneca 1Q Imfinzi Revenue $1.69B, Up 30% at Constant Currency

DJ

Lezen

29 apr 2026, 06:03 UTC

Winsten

AstraZeneca 1Q Tagrisso Revenue $1.83B, Up 5% at Constant Currency

DJ

Lezen

29 apr 2026, 06:02 UTC

Winsten

Analysts Saw AstraZeneca 1Q Core EPS at $2.54

DJ

Lezen

29 apr 2026, 06:01 UTC

Winsten

Analysts Saw AstraZeneca 1Q Revenue at $14.94B

DJ

Lezen

29 apr 2026, 06:01 UTC

Winsten

AstraZeneca Backs 2026 View

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Adj EPS $2.58

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Rev $15.29B

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Pretax Pft $3.91B

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Oper Pft $4.25B

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q Net Pft $3.08B

DJ

Lezen

29 apr 2026, 06:00 UTC

Winsten

AstraZeneca PLC 1Q EPS $1.97

DJ

Lezen

27 apr 2026, 10:48 UTC

Marktinformatie

AstraZeneca Likely Unaffected by Partner Daiichi Sankyo's Supply Review -- Market Talk

DJ

Lezen

10 apr 2026, 11:57 UTC

Marktinformatie

AstraZeneca Likely to Increase Spending to Prepare for New Launches -- Market Talk

DJ

Lezen

10 apr 2026, 10:26 UTC

Marktinformatie
Winsten

AstraZeneca Expected to Reiterate Full-Year Guidance -- Market Talk

DJ

Lezen

2 apr 2026, 09:16 UTC

Marktinformatie

AstraZeneca Liver Cancer Trial Could Help Imfinzi Peak Sales Beat Views -- Market Talk

DJ

Lezen

27 mrt 2026, 10:40 UTC

Marktinformatie

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

DJ

Lezen

27 mrt 2026, 10:17 UTC

Marktinformatie

AstraZeneca Lung Disease Trial Adds Building Block to 2030 Target -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

AstraZeneca PLC Prognose

Koersdoel

By TipRanks

14.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16,076.92 GBX  14.79%

Hoogste 18,600 GBX

Laagste 11,300 GBX

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor AstraZeneca PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

13

Buy

1

Hold

1

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan AstraZeneca PLC - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

81 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Andere aandelen uit de sector

GSK

GlaxoSmithKline PLC

1,913

↓-0.26%
help-icon Live chat